# TCGA-Informed Spatial Profiling Reveals Peripheral CD147 Expression at the Invasive Tumor Front as a Prognostic Indicator in OSCC

**Authors:** Felix Nieberle, Steffen Spoerl, Quirin Strotzer, Robin Hartmann, Ramona Erber, Silvia Spoerl, Johannes G. Schuderer, Katja Himmelstoß, Johannes Meier, Tobias Ettl, Torsten E. Reichert, Juergen Taxis

PMC · DOI: 10.3390/ijms27052172 · International Journal of Molecular Sciences · 2026-02-25

## TL;DR

This study finds that CD147 expression at the edge of oral cancer tumors is linked to better survival, suggesting it could be a useful biomarker for prognosis.

## Contribution

The study identifies peripheral CD147 as a novel, compartment-specific prognostic marker in oral squamous cell carcinoma.

## Key findings

- Low CD147 expression at the tumor invasive front correlates with improved overall survival in OSCC patients.
- CD147 overexpression in tumors is associated with immunosuppressive signaling and resistance-related gene networks.
- CD147 expression in the tumor center or adjacent mucosa has no prognostic significance.

## Abstract

Oral squamous cell carcinoma (OSCC) remains a major cause of cancer-related mortality worldwide, with limited biomarker-driven tools for risk stratification. CD147 is a membrane glycoprotein implicated in tumor metabolism, invasion, immune evasion, and therapy resistance. This study aimed to evaluate the prognostic and predictive relevance of CD147 expression in distinct tumor compartments of OSCC. Formalin-fixed tumor samples from 229 OSCC patients were analyzed via tissue microarray and immunohistochemistry to assess CD147 expression in the tumor center, periphery, and adjacent mucosa. Associations with clinicopathological parameters, survival, and therapy response were evaluated using non-parametric statistical tests, Kaplan–Meier, multivariate Cox, and binary logistic regression analyses. Complementary transcriptomic and immunological analyses were performed using The Cancer Genome Atlas (TCGA), the University of Alabama at Birmingham Cancer data analysis (UALCAN), Tumor and Immune System Interaction Database (TISIDB), and the Genotype-Tissue Expression (GTEx) project’s datasets. Low CD147 expression in the tumor invasive front was independently associated with improved overall survival, while expression in the tumor center or mucosa showed no prognostic value. No significant associations between CD147 and adjuvant therapy response were identified. TCGA-based analyses confirmed CD147 overexpression in tumors and its correlation with immunosuppressive signaling and resistance-associated transcriptional networks. Peripheral CD147 expression serves as a compartment-specific, independent prognostic marker in OSCC in this retrospective single-center cohort. Its spatially restricted prognostic relevance and association with immune modulation and therapy resistance highlight CD147 as a promising candidate for future biomarker-driven and therapeutic strategies.

## Linked entities

- **Genes:** BSG (basigin (Ok blood group)) [NCBI Gene 682]
- **Diseases:** oral squamous cell carcinoma (MONDO:0004958), cancer (MONDO:0004992)

## Full-text entities

- **Genes:** BSG (basigin (Ok blood group)) [NCBI Gene 682] {aka 5F7, CD147, EMMPRIN, EMPRIN, HAb18G, OK}
- **Diseases:** OSCC (MESH:D000077195), Cancer (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12985257/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12985257/full.md

## References

60 references — full list in the complete paper: https://tomesphere.com/paper/PMC12985257/full.md

---
Source: https://tomesphere.com/paper/PMC12985257